I agree 10000000% our AWESOME feature, is, potentially, to treat...

I agree 10000000% our AWESOME feature, is, potentially, to treat the condition totally, glucose control and any underlying consequences - also, look back at our initial Ph2 data, it was SAFE and it showed material efficiency - but remember, safety was what the trial was primarily about, the dosage levels were relatively modest, but the outcomes evidenced clear dose dependency - exactly what Dr's like to see. No-doubt, over the last few months, the Prof and his team have been nutting out the strategy forward, toward a likely 2015 PhIII[1], which should see a few thousand tested and I'd expect to see some participants receive higher cell numbers too!

The above clearly has to factor in the results of the current "complications" trial, but I suspect both the FDA and MSB are going to want to "peddle to mettle" this one- if the safety holds up! Those T2D statistics out of the US would be scaring the hell out of 'em - another reason for their 7 FDA labs now working away on MSC's - clearly something BIG is rapidly building!